Akari Therapeutics (NASDAQ:AKTX) Stock Price Breaks Above Two Hundred Day Moving Average – What’s Next?

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $9.14 and traded as high as $9.33. Akari Therapeutics shares last traded at $9.20, with a volume of 42,294 shares traded.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AKTX shares. Alliance Global Partners upgraded Akari Therapeutics to a “strong-buy” rating in a research report on Friday, September 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Akari Therapeutics in a research note on Friday, October 2nd. Wall Street Zen raised Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd. Finally, Maxim Group raised Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Akari Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $32.33.

Akari Therapeutics Stock Up 7.2%

The company’s 50 day moving average price is $9.27 and its 200 day moving average price is $9.14.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company’s research centers on complement-system and leukotriene biology, which are involved in immune responses and inflammation.

Its lead investigational product is nomacopan, a recombinant protein designed to inhibit complement component C5 and leukotriene B4. Akari is also developing PAS-nomacopan, a longer-acting version intended to extend the therapy’s duration of action.